Free Trial
NASDAQ:STRO

Sutro Biopharma (STRO) Stock Price, News & Analysis

Sutro Biopharma logo
$0.76 +0.00 (+0.13%)
As of 07/3/2025 02:21 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Sutro Biopharma Stock (NASDAQ:STRO)

Key Stats

Today's Range
$0.75
$0.78
50-Day Range
$0.68
$1.10
52-Week Range
$0.52
$5.17
Volume
141,879 shs
Average Volume
1.14 million shs
Market Capitalization
$64.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.11
Consensus Rating
Hold

Company Overview

Sutro Biopharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
64th Percentile Overall Score

STRO MarketRank™: 

Sutro Biopharma scored higher than 64% of companies evaluated by MarketBeat, and ranked 330th out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Sutro Biopharma has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 3 buy ratings, 4 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Sutro Biopharma has only been the subject of 3 research reports in the past 90 days.

  • Read more about Sutro Biopharma's stock forecast and price target.
  • Earnings Growth

    Earnings for Sutro Biopharma are expected to decrease in the coming year, from ($2.92) to ($2.95) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Sutro Biopharma is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Sutro Biopharma is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Sutro Biopharma has a P/B Ratio of 1.42. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Sutro Biopharma's valuation and earnings.
  • Percentage of Shares Shorted

    9.29% of the float of Sutro Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Sutro Biopharma has a short interest ratio ("days to cover") of 5.2.
  • Change versus previous month

    Short interest in Sutro Biopharma has recently increased by 34.28%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Sutro Biopharma does not currently pay a dividend.

  • Dividend Growth

    Sutro Biopharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    9.29% of the float of Sutro Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Sutro Biopharma has a short interest ratio ("days to cover") of 5.2.
  • Change versus previous month

    Short interest in Sutro Biopharma has recently increased by 34.28%, indicating that investor sentiment is decreasing significantly.
  • Search Interest

    Only 2 people have searched for STRO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    4 people have added Sutro Biopharma to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Sutro Biopharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 3.60% of the stock of Sutro Biopharma is held by insiders.

  • Percentage Held by Institutions

    96.99% of the stock of Sutro Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Sutro Biopharma's insider trading history.
Receive STRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sutro Biopharma and its competitors with MarketBeat's FREE daily newsletter.

STRO Stock News Headlines

Get Your Bank Account “Fed Invasion” Ready with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.
Sutro Biopharma downgraded to Neutral from Buy at H.C. Wainwright
See More Headlines

STRO Stock Analysis - Frequently Asked Questions

Sutro Biopharma's stock was trading at $1.84 at the beginning of the year. Since then, STRO stock has decreased by 58.4% and is now trading at $0.7650.

Sutro Biopharma, Inc. (NASDAQ:STRO) posted its quarterly earnings results on Thursday, May, 8th. The company reported ($0.91) earnings per share for the quarter, missing the consensus estimate of ($0.63) by $0.28. The company earned $17.40 million during the quarter, compared to analysts' expectations of $11.61 million. Sutro Biopharma had a negative trailing twelve-month return on equity of 347.60% and a negative net margin of 373.66%.

Sutro Biopharma (STRO) raised $75 million in an initial public offering on Thursday, September 27th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Cowen and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Shares of STRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Sutro Biopharma investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Moderna (MRNA) and Home Depot (HD).

Company Calendar

Last Earnings
5/08/2025
Today
7/04/2025
Next Earnings (Estimated)
8/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:STRO
Fax
N/A
Employees
240
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.11
High Stock Price Target
$17.00
Low Stock Price Target
$0.80
Potential Upside/Downside
+699.3%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
8 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$227.46 million
Net Margins
-373.66%
Pretax Margin
-370.06%

Debt

Sales & Book Value

Annual Sales
$62.04 million
Price / Cash Flow
N/A
Book Value
$0.54 per share
Price / Book
1.42

Miscellaneous

Free Float
81,420,000
Market Cap
$64.61 million
Optionable
Optionable
Beta
1.64
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:STRO) was last updated on 7/5/2025 by MarketBeat.com Staff
From Our Partners